MedImmune Files BLA For Pediatric RSV Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
PDUFA date for Numax (motavizumab) would be Nov. 30 under standard review.
You may also be interested in...
Antibodies Licensed From Trellis Bring MedImmune More Potential RSV Candidates
Using very high throughput screening, Trellis identified antibodies in human blood that had been selected by the immune system to fight the virus.
Antibodies Licensed From Trellis Bring MedImmune More Potential RSV Candidates
Using very high throughput screening, Trellis identified antibodies in human blood that had been selected by the immune system to fight the virus.
Scant Worry Over PDL Patent Challenges
Firm forges ahead with plans to split off biotech operations.